Protocol Ledger

NCT05032040 · Phase II · ACTIVE NOT RECRUITING

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Interventional Phase II clinical trial protocol NCT05032040 sponsored by Xencor in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-21 Enrollment: 170 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05032040
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)170 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05032040
Protocol FieldVerified Registry Value
NCT IdentifierNCT05032040
Consolidated Lead SponsorXencor
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment170 participants (ESTIMATED)
Registered Start Date2022-07-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI